Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.59 |
| ▸ | NQO1 | P15559 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 4/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632732 | 0.88 | CYP1A2 (0.50) | CYP1A2NQO1ACHEBCHEALDH1A1 | |
| SCHEMBL13871406 | 0.86 | CYP1A2 (0.61) | CYP1A2ACHEBCHEALDH1A1KDM4E | |
| SCHEMBL13241083 | 0.85 | TNKS (0.49) | CYP1A2NQO1ACHEBCHEALDH1A1 | |
| SCHEMBL3160337 | 0.84 | CYP2A6 (0.59) | CYP1A2NQO1ACHEBCHEALDH1A1 | |
| SCHEMBL13241086 | 0.84 | HSD17B10 (0.47) | CYP1A2NQO1ACHEBCHEALDH1A1 | |
| SCHEMBL8393507 | 0.81 | NQO1 (0.67) | NQO1ACHEBCHEALDH1A1KDM4E | |
| SCHEMBL29919905 | 0.81 | NQO1 (0.67) | NQO1ACHEBCHEALDH1A1KDM4E | |
| SCHEMBL24773765 | 0.80 | ACHE (0.53) | CYP1A2NQO1ACHEBCHEALDH1A1 | |
| SCHEMBL1402278 | 0.80 | NQO1 (0.50) | NQO1ACHEBCHEALDH1A1KDM4E | |
| SCHEMBL443271 | 0.80 | CYP1A2 (0.57) | CYP1A2NQO1ACHEBCHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-11124520-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibitor and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200181152-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-06-11 | — | — | US | disclosed |
| US-10538527-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-01-21 | — | — | US | disclosed |
| US-20190241571-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2019-08-08 | — | — | US | disclosed |
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-10239880-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170342031-A1 | QUENCHER | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2017-11-30 | — | — | US | disclosed |
| EP-3235876-A1 | QUENCHER | Wako Pure Chemical Industries, Ltd. (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-9624178-B2 | Substituted cyclopenta pyrimidine bicyclic compounds having antitmitotic and/or antitumor activity methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-04-18 | — | — | US | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20150203485-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL, THE PROCESS FOR PREPARING THE SAME AND OLED DEVICE USING THE SAME | EVERDISPLAY OPTRONICS (SHANGHAI) CO., LTD. (CN) | 2015-07-23 | — | — | US | disclosed |
| US-20150203485-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL, THE PROCESS FOR PREPARING THE SAME AND OLED DEVICE USING THE SAME | EVERDISPLAY OPTRONICS (SHANGHAI) CO., LTD. (CN) | 2015-07-23 | — | — | US | disclosed |
| US-20140303188-A1 | Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antitmitotic And/Or Antitumor Activity And Methods Of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2013137479-A1 | DECAHYDROQUINOXALINE DERIVATIVES AND ANALOGS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-09-19 | — | — | WO | disclosed |
| US-20080070086-A1 | Phase-Separated Polymer Electrolyte Membrane, Electrode - Phase-Separated Polymer Electrolyte Membrane Joint Using Same, Method for Manufacture Thereof, and Fuel Cell Using Same | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070086-A1 | Phase-Separated Polymer Electrolyte Membrane, Electrode - Phase-Separated Polymer Electrolyte Membrane Joint Using Same, Method for Manufacture Thereof, and Fuel Cell Using Same | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| EP-0975571-A1 | METHOD FOR PREPARING AROMATIC ALDEHYDES | RHODIA CHIMIE (FR) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047848-A1 | METHOD FOR PREPARING AROMATIC ALDEHYDES | RHODIA CHIMIE (FR) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | CYP1A2 3344/4885NQO1 1630/4885ACHE 4821/4885 |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | CYP1A2 572/4885NQO1 79/4885ACHE 450/4885 |
| US-20150203485-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL, THE PROCESS FOR PREPARING THE SAME AND OLED DEVICE USING THE SAME | OCIAD1, OCIAD2, OR10J3 | CYP1A2 638/4885NQO1 338/4885ACHE 1219/4885 |
| US-20200181152-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | FOLR1, DHFR, TUBB3 | CYP1A2 2994/4885NQO1 4047/4885ACHE 4847/4885 |
| US-20190241571-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | TUBB, TUBB1, TUBA1C | CYP1A2 2560/4885NQO1 4074/4885ACHE 4825/4885 |
| US-10239880-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | FOLR1, TUBB1, TUBA1C | CYP1A2 2570/4885NQO1 4214/4885ACHE 4812/4885 |
| US-20170342031-A1 | QUENCHER | AHR, GFER, AKR1A1 | CYP1A2 56/4885NQO1 130/4885ACHE 2853/4885 |
| US-11124520-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibitor and antitumor agents | FOLR1, DHFR, TUBB3 | CYP1A2 3004/4885NQO1 4065/4885ACHE 4848/4885 |
| US-20140303188-A1 | Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antitmitotic And/Or Antitumor Activity And Methods Of Use Thereof | ABCC1, ABCG2, ABCB1 | CYP1A2 1930/4885NQO1 1473/4885ACHE 3573/4885 |
| US-10538527-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | TUBB, TUBB1, TUBA1C | CYP1A2 2560/4885NQO1 4074/4885ACHE 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.